Introduction
============

Patients with chronic obstructive pulmonary disease (COPD) have shown to have a systemic low-grade inflammation in stable condition ([@b23-copd-2-575]), which transiently increases during acute exacerbations of COPD ([@b49-copd-2-575]; [@b14-copd-2-575]; [@b18-copd-2-575]; [@b41-copd-2-575]). Low-grade systemic inflammation may also be further aggravated during or following high-intensity exercise bouts. In fact, increased systemic inflammation has been observed in patients with clinically stable COPD following 11 minutes of cycling at only ∼40% of peak external work rate as compared to baseline levels ([@b36-copd-2-575]). The acute systemic effects of a single exercise bout may be more apparent in hospitalized patients with COPD, but has never been studied. Nevertheless, an increased systemic inflammation following intensive exercises may also be expected in these patients and may result in additional increased plasma levels of fibrinogen ([@b49-copd-2-575]), energy disbalance ([@b14-copd-2-575]) and skeletal muscle weakness ([@b41-copd-2-575]). Moreover, it may neutralize the beneficial effects that exercise training may have in these patients ([@b29-copd-2-575]). Finally, exercise-induced cytokines may directly inhibit the activity of one of the major growth promoting factors (eg, insulin-like growth factor I (IGF-I)) ([@b22-copd-2-575]). Sequentially, this may reduce its circulating levels, as previously found in healthy adolescent boys ([@b32-copd-2-575]) and in patients with cystic fibrosis ([@b43-copd-2-575]). To date, the acute effects of cycling at a high intensity on circulating levels of IGF-I are unknown in patients with clinically stable COPD or during an acute exacerbation.

Given the possible role of increased systemic inflammation and reduced systemic markers of the somatotrophic axis in the development and/or maintenance of skeletal muscle weakness in patients with COPD ([@b20-copd-2-575]; [@b16-copd-2-575], [@b17-copd-2-575]; [@b41-copd-2-575]), the present study was undertaken to further explore the acute systemic effects of cycling in hospital admitted patients with COPD and in those with stable disease. The authors hypothesized that COPD patients who are admitted to the hospital due to an acute exacerbation would have a higher inflammatory response to a single exercise bout as compared to patients with clinically stable COPD.

Materials and methods
=====================

Patients
--------

Thirty patients with moderate-to-severe COPD (forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) \< 70%) gave informed consent to participate in the present study, which was approved by the Medical Ethical Committee of the University Hospitals Leuven. Fourteen patients (10 men) were hospitalized while the remaining 16 patients (13 men) did not have an acute COPD exacerbation during at least 12 weeks preceding the tests.

Patients with COPD attended the emergency room due to a sustained worsening of the their condition, from the stable state and beyond normal day-to-day variations, that was acute in onset and required a change in regular medication ([@b37-copd-2-575]). The decision to admit patients to the hospital was made by the attending chest physician who was not familiar with the present study protocol. In 2 patients the presence of purulent sputum was documented in the patients' file. In addition, 2 patients were classified as having a type 1 exacerbation, 3 patients had a type 2 exacerbation, while 9 others had a type 3 exacerbation ([@b3-copd-2-575]). Median circulating levels of C-reactive protein was 62.2 mg/l at the emergency room. Hospital admitted patients received 32-milligram · day^−1^ oral methylprednisolone for 1 week, followed by 24-milligram · day^−1^ for a period of 4 days and a subsequent decrease of 4-milligram · week^−1^. No physical exercises were given during the hospital stay.

The acute systemic effects of exercise can be influenced by the intensity and type of the exercise bout ([@b38-copd-2-575]; [@b35-copd-2-575]). Therefore, the patients were asked to perform two different exercise tests on two separate days: a symptom-limited peak exercise test (at day 8 of hospitalization) and a symptom-limited constant-work-rate exercise test at \~70% of the peak external work rate (2--3 days later). In addition, pulmonary function, quadriceps peak torque and the distance walked in 6 minutes were assessed as described previously ([@b24-copd-2-575]). All procedures were in accordance with the recommendations found in the World Medical Association declaration of Helsinki ([@b1-copd-2-575]).

Symptom-limited peak exercise test
----------------------------------

Peak exercise capacity was assessed by a symptom-limited peak exercise test on an electronically braked cycle-ergometer (Ergoline D-72475, Bitz, Germany). After a 2-minute resting period and 3 minutes of unloaded cycling, participants started at 20 watts and cycled until symptom limitation at an incremental workload (+10 watts/minute). Oxygen uptake (Vmax 29C Viasys Meda N.V., Edegem, Belgium), heart rate (Mac VS/ST, Marquette Electronics Inc.) and transcutaneous oxygen saturation (Datex-Ohmeda 3900) were measured during the test. At the end of the test Borg symptom scores for dyspnoea and fatigue were obtained from all participants ([@b6-copd-2-575]). Peak external work rate and peak oxygen uptake were normalized for height, age and gender ([@b26-copd-2-575]).

Symptom-limited constant-work-rate test
---------------------------------------

Endurance exercise capacity was assessed by a symptom-limited constant-work-rate test, which is a reliable and valid method to assess exercise endurance in patients with COPD (van't [@b45-copd-2-575]). This test was performed on the aforementioned cycle-ergometer. After a 2-minute resting period and 3 minutes of unloaded cycling, participants started at ∼70% of their peak external work rate until symptom limitation. At the end of the test Borg symptom scores for dyspnea and fatigue were obtained from all participants.

Blood analyses
--------------

Venous blood samples were drawn before the start of both tests, directly at the end of the tests, and 2 and 30 minutes afterwards. They were directly centrifuged and stored at −80 degrees Celsius. Circulating levels of interleukin 6 (IL-6) and interleukin 8 (CXCL8) were determined using Human Inflammation Cytometric Bead Array (Becton Dickinson Biosciences, San Diego, CA, n = 23) ([@b10-copd-2-575]). C-reactive protein (CRP) was determined using an immunoturbidimetric assay (Roche Diagnostics Corporation, Indianapolis, USA, n = 30). IGF-I was determined using a radio-immuno assay (n = 30) ([@b46-copd-2-575]).

Statistical analyses
--------------------

Results are presented as median (interquartile range, IQR). A Mann-Whitney U test was used to determine possible differences between physiological characteristics of hospitalized and clinically stable patients with COPD. Moreover, possible changes in systemic levels of IL-6, CXCL8, CRP, and IGF-I following exercise were analyzed by using a general linear models procedure repeated measures analysis of variance, incorporating baseline values as covariates. Spearman rank correlations (r) were used to determine relationships. A priori, a two-sided level of significance was set at p ≤ 0.05 ([@b2-copd-2-575]).

Results
=======

Characteristics
---------------

On average, patients had moderate-to-severe COPD, normal body mass index, skeletal muscle weakness and reduced functional and peak exercise capacity ([Table 1](#t1-copd-2-575){ref-type="table"}). As compared with the stable patients, hospitalized patients had significantly lower values for the distance walked in 6 minutes ([Table 1](#t1-copd-2-575){ref-type="table"}). On average, both cycling exercise bouts were limited by reaching the maximal voluntary ventilation. High Borg symptom scores for fatigue and dyspnoea confirmed maximal effort ([Tables 2](#t2-copd-2-575){ref-type="table"} and [3](#t3-copd-2-575){ref-type="table"}). Oxygen uptake, heart rate and ventilation at the end of the symptom-limited constant-work-rate test were equal to the values obtained at the end of the symptom-limited peak exercise test in both groups ([Table 3](#t3-copd-2-575){ref-type="table"}).

As compared to patients who cycled \>10 minutes (n = 12), those with an endurance exercise time of ≤10 minutes (n = 18) were older (69 ± 7 versus 62 ± 10 years, p = 0.02), had a significantly worse FEV~1~ (37 ± 12 versus 57 ± 14% of the reference values, p = 0.0005) and 6-min walking distance (50 ± 18% versus 80 ± 13% of the reference values, p = 0.0001), and tended to be weaker (quadriceps peak torque: 69 ± 29 versus 80 ± 18% of the reference values; and maximal inspiratory mouth pressure: 68 ± 20 versus 82 ± 23% of the reference values, p = 0.08).

Acute anabolic response to exercise tests
-----------------------------------------

At baseline, median circulating levels of IGF-I were not significantly different between the patients admitted to the hospital \[117 μg/l (87 to 149)\] and those with stable disease \[104 μg/l (84 to 123)\]. Median circulating levels of IGF-I increased somewhat between the start of the tests and 2 minutes after ceasing the exercise, directly followed by a reduction to baseline levels 30 minutes after exercise in both tests in both groups ([Figure 1](#f1-copd-2-575){ref-type="fig"}). These changes, however, did not reach the level of significance over time or between groups.

Acute inflammatory response to exercise tests
---------------------------------------------

Median baseline circulating levels of CRP and CXCL8 were not different between the patients admitted to the hospital \[3.7 mg/l (3.0--35.3) and 3.6 pg/ml (1.5--4.7), respectively\] and those with stable disease \[3.4 mg/l (3.0--7.2) and 2.7 pg/ml (2.1--3.5), respectively\]. Neither median circulating levels of CRP (data not shown), nor circulating levels of CXCL8 changed during or 30 minutes after either type of exercise bout in either group ([Figure 2](#f2-copd-2-575){ref-type="fig"}). Baseline systemic IL-6 could only be detected in 22% of the patients, and did not change significantly during or after both exercise tests.

Discussion
==========

The main objective of the present study was to compare the acute systemic anabolic and inflammatory responses following two types of exercise bouts in hospitalized patients with COPD with those of patients with clinically stable COPD. In both groups, IGF-I increased non-significantly with ∼10% directly after exercise, but returned to baseline within 30 minutes. No acute inflammatory response was observed.

Acute systemic anabolic response
--------------------------------

The somatotrophic axis is one of the major pathways of the endocrine system, which is involved in the protein synthesis and subsequent muscle hypertrophy. The present types of exercise did not result in statistically significant increases in circulating levels of IGF-I ([Figure 1](#f1-copd-2-575){ref-type="fig"}). Nevertheless, transient changes in circulating levels of IGF-I during or following high-intensity exercise bouts have been reported ([@b38-copd-2-575]; [@b19-copd-2-575]). Although the source of this transient release of circulating IGF-I remains unknown, different potential origins can be present. Indeed, this may be a result of an increased release of growth hormone ([@b15-copd-2-575]). Nevertheless, the acute exercise-induced increase in circulating levels of IGF-I appears to be independent of the circulating levels of growth hormone and of its response to exercise ([@b8-copd-2-575]; [@b38-copd-2-575]; [@b25-copd-2-575]). In fact, growth-hormone-releasing factor from the hypothalamus influences resting growth hormone secretion by directly stimulating the anterior pituitary gland. In response to growth hormone stimulation, liver cells synthesize insulin-like growth factors (IGF) I, a process requiring between 8 and 30 hours.

Changes in circulating levels of IGF-I most probably do not reflect possible changes in muscle IGF-I mRNA concentration following exercise ([@b4-copd-2-575]). Therefore, studies including muscle biopsies are necessary to understand to what degree acute transient changes in the circulating IGF-I levels are associated with the anabolic effects of one or more bouts of exercise in patients with COPD.

Inflammatory response
---------------------

In the present study, no significant increases have been found in the circulating levels of CRP, IL-6 or CXCL8 during or after symptom-limited peak and constant-work-rate exercise bouts. This is in contrast with the results of Rabinovich and colleagues, who found increased systemic inflammation after cycling for 11 minutes at ∼40% of the achieved peak external work rate (circulating levels of tumor necrosis factor-alpha: +6 pg/ml, without increases of circulating levels of IL-6 or soluble TNF receptors) ([@b36-copd-2-575]). The reason for this discrepancy is unclear. The latter authors suggested that the increased circulating levels of inflammatory markers are related to the exercise-induced muscle damage and the intensity and duration of the exercise ([@b36-copd-2-575]). Exercise bouts at ∼40% of achieved peak external work rate are known to induce muscle damage in patients with COPD ([@b21-copd-2-575]). Unfortunately, in the present study no biopsies of the vastus lateralis muscle were taken. Nevertheless, the present authors expect muscle damage also to be present after exercise bouts at higher intensities (100% and 70% of the peak work load, respectively). Therefore, the duration of the exercise bouts may be the most important factor to induce significant changes in the circulating inflammatory status. Indeed, enormous transient increases in circulating levels of IL-6 and CXCL8 were found 15--30 minutes after prolonged, intense exercise in healthy athletes ([@b34-copd-2-575]; [@b33-copd-2-575]). In addition, higher gene expression of several cytokines, of which the increase in muscle CXCL8 (up to 23.3-fold of baseline values) was the largest after running at ∼70% of the peak oxygen uptake for 3 hours ([@b33-copd-2-575]). So, in the present study the exercise duration was probably too short to induce transient changes in the circulating levels of CRP, IL-6 or CXCL8 (median duration peak exercise test: 5.30 min; median duration constant-work-rate exercise test: 7.30 min). On the other hand, 5 minutes of exhaustive local exercise resulted in increased systemic and local oxidative stress in patients with COPD as compared with healthy age-matched controls ([@b12-copd-2-575], [@b13-copd-2-575]). This topic warrants further investigation.

Clinical implications
---------------------

High-intensity exercise training appears to be the most efficient treatment-modality to partially restore muscle function, exercise tolerance and health-related quality of life in patients with stable COPD ([@b9-copd-2-575]; [@b28-copd-2-575], [@b27-copd-2-575]; [@b5-copd-2-575]; [@b30-copd-2-575]; [@b44-copd-2-575]; [@b40-copd-2-575]). The present study showed no acute systemic inflammatory response to high-intensity cycling bouts which were of a relatively short duration in patients with COPD who recently have been admitted to the hospital. Therefore, it appears that the effects of interval-type of exercise training can be studied in patients with COPD who recently have been discharged from the hospital due to an acute exacerbation of COPD. In fact, [@b29-copd-2-575] found a favorable effect of exercise training on health-related quality of life and functional exercise capacity in patients with COPD directly after discharge from the hospital as compared to a control group. Although the latter study did not report on the intensity and duration of the various exercises, from the current results it can be concluded that on average it is probably safe to perform interval-type of exercises ([@b48-copd-2-575]) in patients that have recently experienced a severe acute exacerbation of COPD.

Older and physically weaker patients with a forced expiratory volume in the first second of around or less than 40% of the predicted values, are not likely to be able to sustain high-intensity endurance-type of exercises. Interval training, resistance training and/or transcutaneous neuromuscular electrical stimulation should be considered in these patients ([@b39-copd-2-575]; [@b11-copd-2-575]; [@b7-copd-2-575]; [@b31-copd-2-575]; [@b40-copd-2-575]; [@b48-copd-2-575]).

Limitations of the study
------------------------

At first sight, it is somewhat surprising that the hospitalized patients and the clinically stable patients had a similar peak exercise tolerance ([Table 2](#t2-copd-2-575){ref-type="table"}) and a significantly different functional exercise capacity eg, the distance walked in 6 minutes ([Table 1](#t1-copd-2-575){ref-type="table"}). Nonetheless, peak exercise capacity has shown be related to pulmonary function impairment (especially tranfer factor for carbon monoxide) ([@b24-copd-2-575]), which was similar between the two groups ([Table 1](#t1-copd-2-575){ref-type="table"}). On the other hand, the distance walked in 6 minutes has shown to be more related to the quadriceps muscle weakness in patients with COPD ([@b24-copd-2-575]), which tended to be significantly different between the two patient groups in the present study.

The severity of the exacerbation may be questioned because hospitalized patients had similar pulmonary function and body mass index as the clinically stable patients ([Table 1](#t1-copd-2-575){ref-type="table"}). Nonetheless, the characteristics and skeletal muscle force of the hospitalized patients were not significantly different from a previous unrelated study ([@b41-copd-2-575]). In contrast, the present clinically stable patients appear to have worse physical characteristics as seen previously ([@b41-copd-2-575]). This is probably because the current patients were free of an acute exacerbation for at least three months, while previously this period was set at 1 year ([@b41-copd-2-575]). Nevertheless, this indicates again that also patients with clinically stable COPD that attend the outpatient consultation of a tertiary care setting are particularly in need of pulmonary rehabilitation ([@b42-copd-2-575]).

The present authors were interested in the acute systemic inflammatory response following a symptom-limited peak exercise test and constant-work-rate exercise test in hospitalized patients who were about to be discharged from the hospital. In the present setting, patients are admitted for about 10 days. Therefore, the symptom-limited peak exercise test had to be done at day 8. Moreover, the patients that Man and colleagues included in their rehabilitation study were also tested after a mean hospital stay of 8 days ([@b29-copd-2-575]). Whether and to what extent exercise-induced increases will occur in systemic inflammation earlier during the acute COPD exacerbation remains unknown. In addition, by only taking blood samples up to 30 minutes after ceasing the exercise tests, the present study may have missed a later inflammatory response. In fact, important changes in inflammatory gene transcription may result from exercise but would probably not have been detected within 30 minutes. Nonetheless, circulating levels of CXCL8 increased significantly following prolonged high-intensity exercise in healthy athletes, with a peak at 30 minutes ([@b34-copd-2-575]).

Finally, the present study did not assess body composition, which recently has been shown to partially influence the exercise-induced systemic inflammatory response in COPD ([@b47-copd-2-575]).

Conclusion
==========

Patients with stable COPD have a reduced physical function ([@b24-copd-2-575]), which deteriorates during an acute exacerbation of COPD ([@b41-copd-2-575]). Therefore, the latter patients have a clear indication to start exercise training following an acute COPD exacerbation. The present study has shown that hospital admitted patients have similar acute systemic responses to high-intensity exercise cycling as compared to the responses of patients with stable disease. Thus, high-intensity cycling exercises for 10 minutes or less seem feasible in patients directly after an acute exacerbation. The present study adds evidence that changes in several inflammatory markers do not occur with exercise in COPD irrespective of their clinical stability.
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###### 

Characteristics

                                  **Whole group**   **Hospitalized patients**   **Stable patients**   **p-value**                          
  ------------------------------- ----------------- --------------------------- --------------------- -------------- ------ -------------- ------
  Sex, M : F                      23                : 7                         10                    : 4            13     : 3            --
  Age, years                      69                (59--74)                    65                    (59--74)       73     (60--75)       0.43
  Height, cm                      165               (160--171)                  162                   (157--169)     167    (163--172)     0.14
  BMI, kg · m^−2^                 25.6              (23.4--29.4)                25.2                  (22.8--29.4)   25.8   (24.9--28.5)   0.92
  FEV~1~, l                       1.09              (0.80--1.43)                1.06                  (0.68--1.37)   1.18   (0.81--1.59)   0.42
  FEV~1~, % reference             42                (33--55)                    41                    (33--54)       45     (33--58)       0.47
  FEV~1~/FVC, %                   39                (35--46)                    38                    (36--45)       42     (34--47)       0.76
  *T*L,CO, mmol kPa^−1^ min^−1^   3.3               (2.6--4.5)                  3.0                   (2.6--4.0)     3.7    (2.5--4.7)     0.42
  *T*L,CO, % reference            42                (34--55)                    41                    (32--51)       50     (35--59)       0.30
  6MWD, m                         398               (257--520)                  251                   (204--507)     439    (338--554)     0.04
  6MWD, % reference               63                (43--78)                    42                    (37--72)       72     (56--85)       0.02
  *P*Imax, % reference            74                (58--83)                    67                    (54--79)       77     (63--88)       0.27
  QPT, % reference                72                (61--89)                    67                    (43--81)       75     (66--93)       0.13

Values are expressed as median (interquartile range), except for gender distribution (absolute numbers). Male (M), female (F), meters (m), body mass index (BMI), body weight in kilograms per square height in metres (kg · m^−2^), forced vital capacity (FVC), litres (l), percent of the reference values (% reference), forced expiratory volume in the first second (FEV~1~), percent (%), transfer factor for carbon monoxide of the lungs (TL,CO), distance walked in 6 minutes (6MWD), meters (m), maximal inspiratory pressure (*P*Imax), and quadriceps peak torque (QPT). p-value: comparison between hospitalized and stable patients with COPD.

###### 

Symptom-limited peak exercise test

                            **Whole group**   **Hospitalized patients**   **Stable patients**   **p-value**                          
  ------------------------- ----------------- --------------------------- --------------------- -------------- ------ -------------- ------
  Peak load, watts          67                (47--100)                   67                    (37--88)       62     (52--113)      0.39
  Peak load, % reference    56                (39--68)                    50                    (41--62)       64     (38--74)       0.31
  Time, s                   325               (210--550)                  345                   (180--460)     309    (245--600)     0.38
  Peak VO~2~, ml·min^−1^    855               (670--1201)                 918                   (669--1147)    802    (680--1258)    0.71
  Peak VO~2~, % reference   51                (34--71)                    47                    (34--76)       52     (35--68)       0.90
  HR, bpm                   129               (119--147)                  132                   (118--149)     128    (121--147)     0.90
  HR, % HRmax calculated    86                (79--92)                    88                    (79--92)       86     (78--95)       0.76
  VE, l·min^−1^             38.6              (31.0--54.7)                43.5                  (23.5--54.7)   36.3   (31.8--52.3)   0.80
  VE/MVV, %                 96                (87--106)                   105                   (90--112)      94     (84--99)       0.10
  Borg dyspnea, points      5                 (5--7)                      5                     (5--9)         6      (4--7)         0.79
  Borg fatigue, points      5                 (4--6)                      4                     (3--5)         5      (4--7)         0.16
  Lactate, mmol             5.71              (4.25--7.87)                6.18                  (4.27--7.67)   5.43   (3.89--8.06)   0.66

Values are expressed as median (interquartile range). Expressed as a percent of the reference values (% reference), seconds (s), oxygen uptake (VO~2~), millilitres per minute (ml · min^−1^), heart rate (HR), beats per minute (bpm), ventilation (VE), litres per minute (l · min--1), and maximum voluntary ventilation (MVV). p-value: comparison between hospitalized and stable patients with COPD.

###### 

Symptom-limited constant-work-rate exercise test

                          **Whole group**   **Hospitalized patients**   **Stable patients**   **p-value**                          
  ----------------------- ----------------- --------------------------- --------------------- -------------- ------ -------------- ------
  Load, watts             47                (27--67)                    48                    (27--62)       42     (36--72)       0.43
  Load, % peak test       69                (63--73)                    71                    (63--73)       67     (62--73)       0.88
  Time, s                 455               (260--880)                  385                   (250--980)     480    (270--805)     0.65
  VO2, ml·min^−1^         867               (659--1202)                 909                   (681--1153)    845    (626--1258)    0.79
  VO2, % peak test        99                (88--106)                   99                    (86--104)      97     (88--107)      0.92
  HR, bpm                 133               (117--146)                  139                   (126--151)     131    (104--143)     0.23
  HR, % peak test         100               (93--107)                   102                   (98--109)      98     (88--106)      0.21
  VE, l·min^−1^           38.1              (30.6--55.7)                44.9                  (25.3--55.7)   34.9   (32.4--53.7)   0.82
  VE/MVV, %               95                (79--114)                   113                   (92--115)      90     (73--95)       0.02
  Borg dyspnoea, points   5                 (4--7)                      4                     (3--6)         7      (4--7)         0.07
  Borg fatigue, points    5                 (4--7)                      5                     (4--7)         5      (4--6)         0.83
  Lactate, mmol           5.66              (4.34--7.64)                6.73                  (5.76--8.82)   4.86   (3.90--5.83)   0.03

Values are expressed as median (interquartile range). Expressed as a percent of the reference values (% reference), seconds (s), oxygen uptake (VO~2~), millilitres per minute (ml · min^−1^), heart rate (HR), beats per minute (bpm), ventilation (VE), litres per minute (l · min^−1^), and maximum voluntary ventilation (MVV). P-value: comparison between hospitalized and stable patients with COPD.
